Retreatment with omalizumab results in rapid remission in chronic spontaneous and inducible urticaria

JAMA Dermatology

Volumn 150, Issue 3, 2014, Pages 288-290

  Metz, Martin ^a   Ohanyan, Tatevik ^a   Church, Martin K ^a   Maurer, Marcus ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

OMALIZUMAB;

ADULT; AGED; ARTICLE; CHRONIC URTICARIA; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE ACTIVITY SCORE; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HUMAN; INJECTION SITE REACTION; MALE; MEDICAL HISTORY; OUTCOME ASSESSMENT; PATIENT ASSESSMENT; PRIORITY JOURNAL; RECURRENT DISEASE; REMISSION; RETREATMENT; RETROSPECTIVE STUDY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AMBULATORY CARE; ANTI-ALLERGIC AGENTS; ANTIBODIES, ANTI-IDIOTYPIC; ANTIBODIES, MONOCLONAL, HUMANIZED; CHRONIC DISEASE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HOSPITALS, UNIVERSITY; HUMANS; INJECTIONS, SUBCUTANEOUS; MALE; MIDDLE AGED; PATIENT SAFETY; RECURRENCE; RETREATMENT; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; URTICARIA; YOUNG ADULT;

EID: 84896074511     PISSN: 21686068     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamadermatol.2013.8705     Document Type: Article

References (14)

1. Kaplan A, Ledford D, Ashby M, et al. Omalizumab in patients with symptomatic chronic idiopathic/spontaneous urticaria despite standard combination therapy. J Allergy Clin Immunol. 2013;132(1):101-109.
2. Maurer M, Altrichter S, Bieber T, et al. Efficacy and safety of omalizumab in patients with chronic urticaria who exhibit IgE against thyroperoxidase. J Allergy Clin Immunol. 2011;128(1):202-209.e5. doi:10.1016/j.jaci.2011.04.038.
3. Maurer M, Rosén K, Hsieh HJ, et al. Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria. N Engl J Med. 2013;368(10):924-935.
4. Saini S, Rosen KE, Hsieh HJ, et al. A randomized, placebo-controlled, dose-ranging study of single-dose omalizumab in patientswith H1-antihistamine-refractory chronic idiopathic urticaria. J Allergy Clin Immunol. 2011;128(3):567-573.e1. doi:10.1016/j.jaci.2011.06.010.
5. Zuberbier T, Asero R, Bindslev-Jensen C, et al Dermatology Section of the European Academy of Allergology and Clinical Immunology; Global Allergy and Asthma European Network; European Dermatology Forum; World Allergy Organization. EAACI/GA(2)LEN/EDF/WAO guideline: management of urticaria. Allergy. 2009;64(10):1427-1443.
6. Metz M, Maurer M. Omalizumab in chronic urticaria. Curr Opin Allergy Clin Immunol. 2012;12(4):406-411.
7. Metz M, Ohanyan T, Church MK, Maurer M. Omalizumab is an effective and rapidly acting therapy in difficult-to-treat chronic urticaria: a retrospective clinical analysis [published online September 23, 2013]. J Dermatol Sci. doi:10.1016/j.jdermsci.2013.08.011.
8. Viswanathan RK, Moss MH, Mathur SK. Retrospective analysis of the efficacy of omalizumab in chronic refractory urticaria. Allergy Asthma Proc. 2013;34(5):446-452.
9. Labrador-Horrillo M, Valero A, Velasco M, et al. Efficacy of omalizumab in chronic spontaneous urticaria refractory to conventional therapy: analysis of 110 patients in real-life practice. Expert Opin Biol Ther. 2013;13(9):1225- 1228.
10. Armengot-Carbo M, Velasco-Pastor M, Rodrigo-Nicolas B, Pont-Sanjuan V, Quecedo-Estebanez E, Gimeno-Carpio E. Omalizumab in chronic urticaria: a retrospective series of 15 cases. Dermatol Ther. 2013;26(3):257-259.
11. Song CH, Stern S, Giruparajah M, Berlin N, Sussman GL. Long-term efficacy of fixed-dose omalizumab for patients with severe chronic spontaneous urticaria. Ann Allergy Asthma Immunol. 2013;110(2):113-117.
12. Nam YH, Kim JH, Jin HJ, et al. Effects of omalizumab treatment in patients with refractory chronic urticaria. Allergy Asthma Immunol Res. 2012;4(6):357-361.
13. Młynek A, Zalewska-Janowska A, Martus P, Staubach P, Zuberbier T, Maurer M. How to assess disease activity in patients with chronic urticaria? Allergy. 2008;63(6):777-780. (Pubitemid 351591864)
14. Corren J, Casale TB, Lanier B, Buhl R, Holgate S, Jimenez P. Safety and tolerability of omalizumab. Clin Exp Allergy. 2009;39(6):788-797.